Europe Breast and Prostate Cancer Diagnostics Industry Outlook from 2023 to 2033
Revenue of breast and prostate cancer diagnostics in Europe totaled US$ 3,949.1 million in 2022 and is expected to reach US$ 4,041.5 million by 2023. Over the assessment period, demand for breast and prostate cancer diagnostics across Europe is set to rise at 2.2% CAGR. By 2033, the total revenue in Europe is expected to reach US$ 5,030.1 million.
Key Highlights of the Report:
Revenue in Europe to Expand Around 1.3X through 2033
Breast and prostate cancer diagnostics revenue in Europe is expected to expand by about 1.3X by 2033. This is attributable to the rising prevalence of breast and prostate cancer, the growing needs for early cancer detection, favorable government support, and advancements in cancer diagnostics technology.
Europe is witnessing a dramatic rise in the cases of breast and prostate cancer. This is creating a surging demand for cancer diagnostic testing in countries across Europe, thereby fostering growth.
Government initiatives and screening programs are anticipated to play key roles in boosting revenue across Europe. Several countries in Europe are launching breast screening programs, which are expected to drive demand in the region.
For instance, the new European Cancer Imaging Initiative was launched in December 2022. Such initiatives will present lucrative opportunities for breast and prostate cancer diagnostics companies.
Other trends in breast and prostate cancer diagnosis space in Europe
Rising demand for minimally invasive surgeries
Growing popularity of non-invasive cancer diagnostic tests
Introduction of favorable reimbursement policies
Increasing preference for biopsies
Advancements in cancer diagnostic equipment in Europe
Growing awareness about the importance of early cancer detection in healthcare
Biopsy and Liquid Biopsy Segments to Collectively Hold 43% Share
As per the latest Europe breast and prostate cancer diagnostics industry analysis, the biopsy and liquid biopsies segment is expected to hold around 43% share through 2033 collectively. This is due to the rising patient preference for biopsies and liquid biopsies due to their high effectiveness and reliable nature.
Biopsies and liquid biopsies are becoming suitable tools for diagnosing breast and prostate cancer. They are the ideal means to diagnose these cancer types definitively. As a result, medical professionals often recommend these cancer diagnostic tests to patients for early cancer detection.
Advancements in biopsy procedures, such as MRI-targeted biopsies, 3D optical biopsies, and ultrasound-guided biopsies, are anticipated to boost the target segments further. As a result, a dominant share has been predicted for biopsy and liquid biopsy segments.
Research and Development Activities Becoming Key Focus of Companies
The rising burden of cancer is triggering innovation in diagnostic and treatment approaches. Both governments and critical companies are spending rigorously in research & development activities to advance cancer diagnostics and develop new and more effective cancer diagnostics tests.
Ongoing research in breast cancer diagnostics, including developing new biomarkers and genetic testing methods, is set to facilitate growth in Europe. Similarly, the introduction and popularity of targeted therapies & personalized diagnostics approaches will bode well for this business.
Companies are also exploring new imaging techniques, such as digital breast tomosynthesis (DBT), that detect smaller and earlier-stage tumors than conventional mammograms. This is expected to strengthen their regional presence and boost their revenue.
Industry Outlook
Attributes
Key Insights
Base Value (2022)
US$ 3,949.1 million
Estimated Value (2023)
US$ 4,041.5 million
Projected Value (2033)
US$ 5,030.1 million
CAGR (2023 to 2033)
2.2%
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Europe Breast and Prostate Cancer Diagnostics Overview
Breast and prostate cancer diagnostics represent a remarkable opportunity due to high precision, reduced invasiveness, and government policies. Effectively developing breast and prostate cancer diagnostics requires a comprehensive harnessing of expertise in diagnostic technologies.
In cancer diagnosis, groundbreaking technologies and innovations such as telehealth, artificial intelligence, CRISPR, cryo-electron microscopy, the Infinium Assay, and robotic surgery are instrumental in advancing and revolutionizing the diagnostic process. The rising popularity of these technologies is expected to boost revenue across Europe.
The growing prevalence of breast and prostate cancer across Europe triggers demand for cancer diagnostics. In recent years, there has been a spike in breast and prostate cancer cases in Europe. As per Globocan 2020, there were around 531086 new breast cancer cases and 473344 prostate cancer cases in Europe.
To counter the burden of cancer, early detection and treatment is necessary. As a result, people across Europe often opt for several cancer diagnostic procedures. This is expected to boost revenue in the region.
Historical Europe Breast and Prostate Cancer Diagnostics Analysis Vs. Forecast
Europe breast and prostate cancer diagnostics revenue accounted for around 0.02% of Europe's cancer diagnostics sales (valued at US$ 16.7 billion) in 2022. In the forecast period, Europe's breast and prostate diagnostics revenue is set to increase at 2.2% CAGR, reaching US$ 5,030.1 million by 2033.
The increasing focus on population-based cancer screening and early detection programs in countries across Europe represents a significant opportunity for diagnostic companies specializing in cancer diagnostics and imaging technologies. These initiatives reflect a proactive approach to addressing the burden of cancer, as early detection is often a critical factor in improving patient outcomes and reducing healthcare costs associated with advanced-stage cancer treatment.
Imaging technologies are also crucial in cancer screening and early detection programs. Advanced imaging modalities, such as mammography, computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound, are employed to visualize potential cancerous lesions, enabling clinicians to make timely and accurate diagnoses.
Europe's thriving landscape of clinical trials and research collaborations focused on cancer diagnostics and treatment has positioned the continent as a hub for innovation and advancement in the fight against cancer. Due to the above factors, Europe is expected to hold a prominent global revenue share.
Increasing breast and prostate cancer cases have become a serious concern across Europe. The disease not only results in loss of lives but also impacts the economic condition of countries. As a result, the government and other healthcare organizations are taking initiatives to counter this cancer burden, creating opportunities for companies.
Find your sweet spots for generating winning opportunities in this market.
Insights into Lucrative Opportunities Propelling Growth in Europe
Advancements in molecular diagnostics, particularly in Europe, are revolutionizing the landscape of cancer diagnosis and treatment. Europe has emerged as a leader in developing and applying cutting-edge molecular diagnostic technologies, such as next-generation sequencing (NGS) and liquid biopsy techniques.
The demand for NGS is expected to rise in Europe owing to its ability to identify specific genetic mutations, alterations, and variations in a patient's tumor DNA. These genetic insights would help provide critical information about the tumor's characteristics, such as its aggressiveness, susceptibility to targeted therapies, and potential resistance mechanisms.
Liquid biopsy techniques represent another remarkable advancement in molecular diagnostics. These non-invasive tests are projected to help analyze several biomarkers, such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and specific proteins in bodily fluids, including blood or urine.
Liquid biopsies are further anticipated to offer several advantages over traditional tissue biopsies, including minimal invasiveness and the ability to monitor disease progression over time. Another factor pushing their demand is the potential for early detection and treatment adjustment. The rising popularity of these cancer diagnostics tests will likely foster growth in Europe.
The growing research & technological advances are expected to create new opportunities for local and global manufacturers entering Europe. This is anticipated to boost Europe’s share in the worldwide breast and prostate cancer diagnostics business.
Factors Challenging Europe Breast and Prostate Cancer Diagnostics Business
The high costs associated with diagnostic tests and imaging techniques for breast and prostate cancer present a significant barrier to access for several patients, particularly those in areas with limited healthcare resources. This financial burden is projected to affect individuals and strain healthcare systems, contributing to disparities in cancer care and outcomes.
One of the primary cost factors in cancer diagnostics is the price of medical equipment and technology. State-of-the-art imaging devices, such as MRI machines, CT scanners, and high-resolution ultrasound equipment, are expected to be essential for accurate cancer diagnosis and staging.
The advanced machines come with substantial price tags, making them less accessible in resource-constrained settings. Additionally, the maintenance and upgrading of such equipment require ongoing investments, further adding to the financial strain on healthcare facilities.
The need for timely and regular screenings further exacerbates the financial burden of cancer diagnostics. Early detection is crucial for improving cancer outcomes, but the need for frequent mammograms, prostate-to-specific antigen (PSA) tests, or other screening methods can strain household budgets. This is especially difficult for individuals without adequate health insurance coverage.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Comparative View of Adjacent Businesses
The breast and prostate cancer diagnostics business in Europe will likely be impacted by the tangential or peer firms in the healthcare division. These include cancer diagnostics and mammography. Knowledge of these related fields can help companies get an in-depth analysis of the overall scenario and frame their strategies accordingly.
Europe Breast and Prostate Cancer Diagnostics Industry Analysis:
Attributes
Europe Breast and Prostate Cancer Diagnostics Industry Analysis
CAGR (2023 to 2033)
2.2%
Sales Value (2033)
US$ 5,030.1 million
Growth Factor
The rising prevalence of breast and prostate cancer is a prominent factor driving demand for breast and prostate cancer diagnostics.
Key Trend
The surging popularity of tests, such as liquid biopsies, is a crucial trend impacting growth across Europe.
Cancer Diagnostics Demand Outlook:
Attributes
Cancer Diagnostics Demand Outlook
CAGR (2023 to 2033)
8.5%
Sales Value (2033)
US$ 126.0 billion
Growth Factor
The increasing incidence of several cancer forms and the growing need for early cancer detection are key factors driving demand for cancer diagnostics.
Key Trend
Rising adoption of AI in cancer diagnostics is a key trend impacting growth.
Mammography Industry Analysis:
Attributes
Mammography Industry Analysis
CAGR (2023 to 2033)
10.1%
Sales Value (2033)
US$ 4899.7 million
Growth Factor
Increasing breast cancer cases and favorable government support will boost the mammography business.
Key Trend
Technological advancements in mammography systems are anticipated to facilitate growth through 2033.
Country-wise Insights
The below table shows the estimated growth rates of the top countries. Spain, France, and Germany are set to record higher CAGRs of 3.1%, 2.4%, and 2.1%, respectively, through 2033.
Growth Outlook by Key Countries
Countries
Value-based CAGR
United Kingdom
1.5%
Germany
2.1%
Spain
3.1%
Italy
1.8%
France
2.4%
Rising Cases of Prostate Cancer Elevating Demand in the United Kingdom
The United Kingdom is expected to remain a key country across Europe regarding breast and prostate cancer diagnostics. It is projected to attain a total valuation of US$ 667.7 million by 2033.
Demand for breast and prostate cancer diagnostics in the United Kingdom will likely rise at 1.5% CAGR during the assessment period. This is attributable to the rising prevalence of prostate cancer, favorable government support, and the growing popularity of tests such as biopsies.
Prostate cancer has risen to become the third-leading cause of cancer-related fatalities in the United Kingdom, surpassing breast cancer, despite notable improvements in survival rates for both diseases. This rise in prostate cancer cases prompts people to opt for several diagnostic tests nationwide.
According to the World Cancer Research Fund, over 150 cases of prostate cancer are diagnosed in the United Kingdom every day. This is expected to create a rising demand for prostate-specific antigen (PSA) screening and other tests. It is further anticipated to present new growth prospects for breast and prostate diagnostic companies in the country.
Prostate-specific antigen (PSA) screening has shown its potential to reduce prostate cancer mortality rates significantly. This blood test is anticipated to witness high demand as it allows for timely intervention by detecting prostate cancer at an early stage. The adoption of these tests is expected to boost revenue in the country.
Recognizing the importance of early detection and improved outcomes, the government is taking proactive steps to introduce new policies and initiatives related to PSA screening. These policies aim to increase awareness about the benefits of PSA testing, encourage routine screening for at-risk populations, and ensure that healthcare providers offer this screening as part of their preventive care services.
Rising Incidence of Breast Cancer in Germany Creating Opportunities for Players
Germany is projected to dominate the Europe breast and prostate cancer diagnostics business by 2033. It is set to experience a CAGR of 2.1% during the forecast period. By 2033, total sales in Germany are expected to reach US$ 837.2 million.
The ongoing and progressive aging of Germany's population is anticipated to drive the demand for cancer screening. According to recent studies conducted in Germany, breast cancer was diagnosed at an older age in 2022 than in 2010.
Breast cancer is also considered the most prevalent cancer among women in Germany, making it a significant public health concern that substantially impacts individuals and the healthcare system. Hence, the growing prevalence of breast cancer in older women is expected to fuel demand in the country.
Advances in Cancer Diagnostics Technology Shaping Growth in France
As per the Europe breast and prostate cancer diagnostics industry analysis, France is expected to witness a CAGR of 2.4% during the forecast period. It is anticipated to attain a valuation of US$ 561.5 million by 2033.
Several factors are expected to drive breast and prostate cancer diagnostics demand in France and facilitate growth. These include the increasing incidence of prostate cancer, rising awareness of early cancer detection, advances in cancer diagnostics technology, and favorable reimbursement policies.
Companies operating in France are actively investing in research & development activities to promote cancer diagnostics. This has paved the way for developing more accurate and sensitive tests, including liquid biopsies. The growing popularity of these advanced and non-invasive procedures is expected to boost revenue in France.
The government in France reimburses the cost of several cancer diagnostics tests. This is projected to make them more affordable to patients, driving their demand.
Category-wise Insights
The below section predicts the biopsy segment to retain its dominance during the forecast period. It is projected to thrive at 1.7% CAGR through 2033. The imaging segment is anticipated to witness a steady CAGR of 2.8% in the forecast period.
Biopsy Remains the Most Opted Test for Breast and Prostate Diagnosis
Growth Outlook by Key Test
Test
Value-based CAGR
Tumor Biomarkers Tests
2.5%
Imaging
2.8%
Biopsy
1.7%
Liquid Biopsy
2.4%
Immunohistochemistry
1.4%
In Situ Hybridization
2.1%
By test, the biopsy segment held a 32.2% share in Europe in 2022. The demand for biopsies across the region is projected to rise at a CAGR of 1.7% during the assessment period. It is set to total a valuation of US$ 1,532.0 million by 2033.
Biopsy has become an ideal test for early diagnosis of cancer types, such as breast and prostate cancer. Its demand is anticipated to surge among patients as it is the only way to determine if a suspicious area is cancerous.
Biopsy is gaining traction due to additional information and the available post-to-research options. The information obtained from a biopsy is expected to help in staging cancer, which is essential for determining the extent of the disease and guiding treatment decisions.
Different types of biopsies would be used to diagnose breast and prostate cancer. For instance, women diagnosed with breast cancer often opt for a core needle biopsy. On the other hand, a transrectal ultrasound (TRUS)-guided biopsy has become a commonly opted type for prostate cancer.
High effectiveness and quick & reliable results are expected to fuel the demand for biopsies across Europe during the forecast period. The usage of imaging guidance, such as MRI or ultrasound, is also making biopsies attractive options for patients.
Breast Cancer to Generate Significant Revenues for Companies
In the table below, the report has been analyzed based on indication. Out of the two indications, the breast cancer segment is anticipated to witness a CAGR of 1.9% in the assessment period. The prostate cancer segment, on the other hand, will likely exhibit a 2.5% from 2023 to 2033.
Growth Outlook by Key Indication
Indication
Value-based CAGR
Breast Cancer
1.9%
Prostate Cancer
2.5%
Based on indication, the breast cancer segment is anticipated to generate a revenue of US$ 2,552.6 million by 2033, holding a prominent share of 50.7%. This is attributable to the rising prevalence of breast cancer, growing cancer awareness, and increasing need for detecting breast cancer in its early stages to initiate proper treatment approaches.
Breast cancer has benefited significantly from early detection efforts, such as mammography screening and increased awareness. Routine screening is expected to allow for the identification of breast cancer at earlier, more treatable stages.
Robust research funding, breast cancer awareness campaigns, and advocacy efforts have all contributed to the improved prognosis by promoting early diagnosis, research breakthroughs, and improved treatment options. This, in turn, is expected to boost the target segment.
Hospital-associated Labs to Hold a Dominant Share
The report is analyzed in the table below based on the end user. Out of the five end users, the hospital-associated labs segment is anticipated to witness a CAGR of 2.0% in the assessment period. The independent diagnostic laboratories segment, on the other hand, will likely exhibit a 2.5% from 2023 to 2033.
Growth Outlook by Key End User
End User
Value-based CAGR
Hospital-associated Labs
2.0%
Independent Diagnostic Laboratories
2.5%
Diagnostic Imaging Centers
2.3%
Cancer Research Institutes
3.0%
Others
1.5%
In Europe, hospital-associated labs hold a significant presence, representing a 44.6% share of the total value in 2022. The target segment is expected to thrive at a CAGR of 2.0% throughout the forecast period. This is attributable to the rising number of hospitals and patient inclination toward cancer diagnosis at hospitals.
Hospitals typically offer a wide range of diagnostic services under one roof, including advanced imaging technologies (MRI, CT scans, and PET scans), laboratory facilities for blood tests & biopsies, and access to specialists in several medical disciplines. This comprehensive approach is anticipated to ensure patients receive a thorough evaluation and diagnosis efficiently.
Competitive Landscape
Organizations and manufacturers with robust procurement capabilities are well-positioned to foster growth and expand their businesses by collaborating with buyers & suppliers. They can innovate and create products that mutually enhance revenues and profits. Employing a holistic approach, they implement multiple strategies, including agreements, acquisitions, collaborations, and expansion, to drive progress and innovation in cancer diagnostics.
Recent Developments
In December 2022, Digistain unveiled a novel breast cancer diagnostics technology that could effectively prevent deaths and save money for organizations, including the National Health Service (NHS).
In December 2022, Cromwell Hospital and Bupa UK Insurance opened a new Specialist Center. Prostate cancer patients now have quick access to diagnostic testing.
In August 2022, Roche introduced a cutting-edge digital PCR system. It is a highly potent diagnostic platform designed to advance the battle against cancer and several other diseases.
Scope of the Europe Breast and Prostate Cancer Diagnostics Industry Analysis
Attribute
Details
Estimated Value (2023)
US$ 4,041.5 million
Projected Value (2033)
US$ 5,030.1 million
Predicted CAGR (2023 to 2033)
2.2%
Forecast Period
2023 to 2033
Historical Data Available for
2018 to 2022
Industry Analysis
Value (US$ million)
Key Regions Covered
Western Europe, Eastern Europe, and the Rest of Europe
Key Countries Covered
Germany, France, Spain, Italy, BENELUX, Nordic Countries, United Kingdom, Poland, Hungary, Romania, Czech Republic
Key Segments Covered
Test, Indication, End User, and Region
Key Companies Profiled
Koninklijke Philips N.V.
F.Hoffmann to La Roche Ltd.
Abbott Laboratories, Inc.
Bio Rad Laboratories Inc.
General Electric (GE HealthCare)
QIAGEN N.V.
Agilent Technologies, Inc.
Becton, Dickinson and Company
Cook Group Inc.
Danaher (Cepheid)
Siemens Healthcare GmbH
Thermo Fisher Scientific Inc.
Illumina, Inc.
Hologic, Inc
Argon Medical Devices
Vortex Biosciences, Inc.
Canon Medical Systems Corporation
Merit Medical Systems
Report Coverage
Forecast, Competition Intelligence, Key Dynamics and Challenges, Strategic Growth Initiatives
Europe Breast and Prostate Cancer Diagnostics Industry Outlook by Category
By Test:
Tumor Biomarkers Tests
PSA Tests
CTC Tests
HER2 Tests
BRCA Tests
Others
Imaging
Ultrasound
Mammography
MRI Scan
PET Scan
CT Scan
SPECT & Others
Biopsy
Needle Biopsy
Endoscopic Biopsy
Bone Marrow Biopsy
Others
Liquid Biopsy
CTCs (Circulatory Tumor Cells)
ctNA (Circulating Tumor Nucleic Acid)
Immunohistochemistry
In Situ Hybridization
By Indication:
Breast Cancer
Invasive Ductal Carcinoma
Ductal Carcinoma in Situ
invasive Lobular Carcinoma
Triple Negative Breast Cancer
Others
Prostate Cancer
Adenocarcinoma
Squamous Cell Carcinoma
Transitional Cell Carcinoma
Neuroendocrine Tumors
Others
By End User:
Hospital Associated Labs
Independent Diagnostic Laboratories
Diagnostic Imaging Centers
Cancer Research Institutes
Others
By Region:
Western Europe
Eastern Europe
Rest of Europe
Frequently Asked Questions
How big is the breast and prostate cancer diagnostics business in Europe?
The total revenue in Europe is estimated to reach US$ 4,041.5 million in 2023.
What is the sales forecast for breast and prostate cancer diagnostics in Europe?
Sales in Europe are projected to total US$ 5,030.1 million by 2033.
What is the demand outlook for breast and prostate cancer diagnostics in Europe?
Demand in Europe is forecast to rise at 2.2% CAGR through 2033.
What was the last seven years’ growth rate for Europe breast and prostate cancer diagnostics?
Sales across Europe grew at a CAGR of 1.6% between 2018 and 2022.
What are the key trends impacting sales growth in Europe?
Continuous advancements in cancer diagnostics and rising cancer awareness are vital trends.
Which are the top five countries driving demand across Europe?
The top countries driving demand are the United Kingdom, Germany, France, Poland, and Italy.
How is breast cancer diagnosed?
Breast cancer is generally diagnosed through imaging tests and biopsies.
What is the United Kingdom breast and prostate cancer diagnostics industry share?
The United Kingdom held a revenue share of US$ 565.4 million in 2022.
What is the demand outlook for Poland?
In 2022, Poland had a value share of around 9.9% in Europe.
What is the outlook of Germany?
Germany is set to thrive at a CAGR of around 2.1% over the forecast period.
Who are the key players in Europe breast and prostate cancer diagnostics sphere?
Koninklijke Philips N.V. and F.Hoffmann are the key players across Europe.
Table of Content
1. Executive Summary
1.1. Europe Industry Outlook
1.2. Demand Side Trends
1.3. Supply-Side Trends
1.4. Analysis and Recommendations
2. Demand Analysis Overview
2.1. Coverage / Taxonomy
2.2. Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Trends
3.1. Key Trends Impacting Growth
3.2. Development/Innovation Trends
4. Value-Added Insights
4.1. Product Adoption Analysis
4.2. Disease Epidemiology
4.3. Reimbursement Landscape
4.4. Key Developments
4.5. Europe Regulatory Scenario
4.6. PESTEL Analysis
4.7. Porters Analysis
4.8. Supply Chain Analysis
4.9. Unmet needs and Opportunities
5. Background
5.1. Macro-Economic Factors
5.1.1. Europe Healthcare Expenditure
5.1.2. Life Science Spending Outlook
5.1.3. Overall Cancer Diagnostics Industry Outlook
5.2. Forecast Factors - Relevance and Impact
5.2.1. Cancer Incidence and Prevalence
5.2.2. Advancements in Diagnostic Technologies
5.2.3. Screening Programs
5.2.4. Genomic Data Sharing and Research Collaborations
5.2.5. Strategic Collaborations
5.2.6. Cancer Survivorship Programs
5.2.7. Biomarker Discovery and Validation
5.2.8. Health Technology Assessment (HTA)
5.2.9. Cancer Screening Controversies
5.3. Key Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. Demand (in Value or Size in US$ million) Analysis 2018 to 2022 and Forecast, 2022 to 2033
6.1. Historical Sales Value (US$ million) Analysis, 2018 to 2022
6.2. Current and Future Value (US$ million) Projections, 2022 to 2033
6.2.1. Y-o-Y Growth Trend Analysis
6.2.2. Absolute $ Opportunity Analysis
7. Analysis 2018 to 2022 and Forecast 2022 to 2033, By Test
7.1. Introduction / Key Findings
7.2. Historical Size (US$ million) Analysis By Test, 2018 to 2022
7.3. Current and Future Size (US$ million) Analysis and Forecast By Test, 2022 to 2033
7.3.1. Tumor Biomarkers Tests
7.3.1.1. PSA Tests
7.3.1.2. CTC Tests
7.3.1.3. HER2 Tests
7.3.1.4. BRCA Tests
7.3.1.5. Others
7.3.2. Imaging
7.3.2.1. Ultrasound
7.3.2.2. Mammography
7.3.2.3. MRI Scan
7.3.2.4. PET Scan
7.3.2.5. CT Scan
7.3.2.6. SPECT and Others
7.3.3. Biopsy
7.3.3.1. Needle Biopsy
7.3.3.2. Endoscopic Biopsy
7.3.3.3. Bone Marrow Biopsy
7.3.3.4. Others
7.3.4. Liquid Biopsy
7.3.4.1. CTCs (Circulatory Tumor Cells)
7.3.4.2. ctNA (Circulating Tumor Nucleic Acid)
7.3.5. Immunohistochemistry
7.3.6. In Situ Hybridization
7.4. Attractiveness Analysis By Test
8. Analysis 2018 to 2022 and Forecast 2022 to 2033, By Indication
8.1. Introduction / Key Findings
8.2. Historical Size (US$ million) By Indication, 2018 to 2022
8.3. Current and Future Size (US$ million) Analysis and Forecast By Indication, 2022 to 2033
8.3.1. Breast Cancer
8.3.1.1. Invasive Ductal Carcinoma
8.3.1.2. Ductal Carcinoma in Situ
8.3.1.3. invasive Lobular Carcinoma
8.3.1.4. Triple Negative Breast Cancer
8.3.1.5. Others
8.3.2. Prostate Cancer
8.3.2.1. Adenocarcinoma
8.3.2.2. Squamous Cell Carcinoma
8.3.2.3. Transitional Cell Carcinoma
8.3.2.4. Neuroendocrine Tumors
8.3.2.5. Others
8.4. Attractiveness Analysis By Indication
9. Sales Analysis 2018 to 2022 and Forecast 2022 to 2033, By End User
9.1. Introduction / Key Findings
9.2. Historical Size (US$ million) By End User, 2018 to 2022
9.3. Current and Future Size (US$ million) Analysis and Forecast By End User, 2022 to 2033
9.3.1. Hospital Associated Labs
9.3.2. Independent Diagnostic Laboratories
9.3.3. Diagnostic Imaging Centers
9.3.4. Cancer Research Institutes
9.3.5. Others
9.4. Attractiveness Analysis By End User
10. Analysis 2018 to 2022 and Forecast 2022 to 2033, By Region
10.1. Introduction / Key Findings
10.2. Historical Size (US$ million) Trend Analysis by Region, 2018 to 2022
10.3. Current and Future Size (US$ million) Analysis and Forecast by Region, 2022 to 2033
10.3.1. Western Europe
10.3.1.1. United Kingdom
10.3.1.2. Germany
10.3.1.3. France
10.3.1.4. Italy
10.3.1.5. Spain
10.3.1.6. BENELUX
10.3.1.7. Nordics
10.3.2. Eastern Europe
10.3.2.1. Poland
10.3.2.2. Hungary
10.3.2.3. Romania
10.3.2.4. Russia
10.3.2.5. Czech Republic
10.3.3. Rest of Europe
10.4. Attractiveness Analysis by Region
11. United Kingdom Demand Analysis 2018 to 2022 and Forecast 2022 to 2033
11.1. Introduction
11.2. Historical Size (US$ million) Analysis by Taxonomy, 2018 to 2022
11.3. Current and Future Size (US$ million) Analysis and Forecast by Taxonomy, 2022 to 2033
11.3.1. By States
11.3.1.1. England
11.3.1.2. Wales
11.3.1.3. Northern Ireland
11.3.1.4. Scotland
11.3.2. By Test
11.3.3. By Indication
11.3.4. By End User
11.4. Attractiveness Analysis
11.4.1. By States
11.4.2. By Test
11.4.3. By Indication
11.4.4. By End User
11.5. State-Level Analysis and Forecast
11.5.1. England Demand Analysis
11.5.1.1. Introduction
11.5.1.2. Demand Analysis and Forecast by Taxonomy
11.5.1.2.1. Test
11.5.1.2.2. By Indication
11.5.1.2.3. By End User
11.5.2. Wales Demand Analysis
11.5.2.1. Introduction
11.5.2.2. Demand Analysis and Forecast by Taxonomy
11.5.2.2.1. Test
11.5.2.2.2. By Indication
11.5.2.2.3. By End User
11.5.3. Northern Ireland Demand Analysis
11.5.3.1. Introduction
11.5.3.2. Demand Analysis and Forecast by Taxonomy
11.5.3.2.1. Test
11.5.3.2.2. By Indication
11.5.3.2.3. By End User
11.5.4. Scotland Demand Analysis
11.5.4.1. Introduction
11.5.4.2. Demand Analysis and Forecast by Taxonomy
11.5.4.2.1. Test
11.5.4.2.2. By Indication
11.5.4.2.3. By End User
12. Germany Demand Analysis 2018 to 2022 and Forecast 2022 to 2033
12.1. Introduction
12.2. Historical Size (US$ million) Analysis by Taxonomy, 2018 to 2022
12.3. Current and Future Size (US$ million) Analysis and Forecast by Taxonomy, 2022 to 2033
12.3.1. By States
12.3.1.1. Baden-Württemberg
12.3.1.2. Bavaria
12.3.1.3. Lower Saxony
12.3.1.4. Hesse
12.3.1.5. Rest of Germany
12.3.2. By Test
12.3.3. By Indication
12.3.4. By End User
12.4. Attractiveness Analysis
12.4.1. By States
12.4.2. By Test
12.4.3. By Indication
12.4.4. By End User
12.5. States Level Analysis and Forecast
12.5.1. Baden-Württemberg Demand Analysis
12.5.1.1. Introduction
12.5.1.2. Demand Analysis and Forecast by Taxonomy
12.5.1.2.1. Test
12.5.1.2.2. By Indication
12.5.1.2.3. By End User
12.5.2. Bavaria Demand Analysis
12.5.2.1. Introduction
12.5.2.2. Demand Analysis and Forecast by Taxonomy
12.5.2.2.1. Test
12.5.2.2.2. By Indication
12.5.2.2.3. By End User
12.5.3. Argentina Demand Analysis
12.5.3.1. Introduction
12.5.3.2. Demand Analysis and Forecast by Taxonomy
12.5.3.2.1. Test
12.5.3.2.2. By Indication
12.5.3.2.3. By End User
12.5.4. Lower Saxony Demand Analysis
12.5.4.1. Introduction
12.5.4.2. Demand Analysis and Forecast by Taxonomy
12.5.4.2.1. Test
12.5.4.2.2. By Indication
12.5.4.2.3. By End User
12.5.5. Hesse Demand Analysis
12.5.5.1. Introduction
12.5.5.2. Demand Analysis and Forecast by Taxonomy
12.5.5.2.1. Test
12.5.5.2.2. By Indication
12.5.5.2.3. By End User
13. Spain Demand Analysis 2018 to 2022 and Forecast 2022 to 2033
13.1. Introduction
13.2. Historical Size (US$ million) Analysis by Taxonomy, 2018 to 2022
13.3. Current and Future Size (US$ million) Analysis and Forecast by Taxonomy, 2022 to 2033
13.3.1. By States
13.3.1.1. Madrid
13.3.1.2. Barcelona
13.3.1.3. Valencia
13.3.1.4. Seville
13.3.1.5. Rest of Spain
13.3.2. By Test
13.3.3. By Indication
13.3.4. By End User
13.4. Attractiveness Analysis
13.4.1. By States
13.4.2. By Test
13.4.3. By Indication
13.4.4. By End User
13.5. States Level Analysis and Forecast
13.5.1. Madrid Demand Analysis
13.5.1.1. Introduction
13.5.1.2. Demand Analysis and Forecast by Taxonomy
13.5.1.2.1. Test
13.5.1.2.2. By Indication
13.5.1.2.3. By End User
13.5.2. Barcelona Demand Analysis
13.5.2.1. Introduction
13.5.2.2. Demand Analysis and Forecast by Taxonomy
13.5.2.2.1. Test
13.5.2.2.2. By Indication
13.5.2.2.3. By End User
13.5.3. Valencia Demand Analysis
13.5.3.1. Introduction
13.5.3.2. Demand Analysis and Forecast by Taxonomy
13.5.3.2.1. Test
13.5.3.2.2. By Indication
13.5.3.2.3. By End User
13.5.4. Seville Demand Analysis
13.5.4.1. Introduction
13.5.4.2. Demand Analysis and Forecast by Taxonomy
13.5.4.2.1. Test
13.5.4.2.2. By Indication
13.5.4.2.3. By End User
14. Italy Demand Analysis 2018 to 2022 and Forecast 2022 to 2033
14.1. Introduction
14.2. Historical Size (US$ million) Analysis by Taxonomy, 2018 to 2022
14.3. Current and Future Size (US$ million) Analysis and Forecast by Taxonomy, 2022 to 2033
14.3.1. By States
14.3.1.1. Rome
14.3.1.2. Abruzzo
14.3.1.3. Basilicata
14.3.1.4. Calabria
14.3.1.5. Rest of Italy
14.3.2. By Test
14.3.3. By Indication
14.3.4. By End User
14.4. Attractiveness Analysis
14.4.1. By States
14.4.2. By Test
14.4.3. By Indication
14.4.4. By End User
14.5. States Level Analysis and Forecast
14.5.1. Rome Demand Analysis
14.5.1.1. Introduction
14.5.1.2. Demand Analysis and Forecast by Taxonomy
14.5.1.2.1. Test
14.5.1.2.2. By Indication
14.5.1.2.3. By End User
14.5.2. Abruzzo Demand Analysis
14.5.2.1. Introduction
14.5.2.2. Demand Analysis and Forecast by Taxonomy
14.5.2.2.1. Test
14.5.2.2.2. By Indication
14.5.2.2.3. By End User
14.5.3. Basilicata Demand Analysis
14.5.3.1. Introduction
14.5.3.2. Demand Analysis and Forecast by Taxonomy
14.5.3.2.1. Test
14.5.3.2.2. By Indication
14.5.3.2.3. By End User
14.5.4. Calabria Demand Analysis
14.5.4.1. Introduction
14.5.4.2. Demand Analysis and Forecast by Taxonomy
14.5.4.2.1. Test
14.5.4.2.2. By Indication
14.5.4.2.3. By End User
15. France Demand Analysis 2018 to 2022 and Forecast 2022 to 2033
15.1. Introduction
15.2. Historical Size (US$ million) Analysis by Taxonomy, 2018 to 2022
15.3. Current and Future Size (US$ million) Analysis and Forecast by Taxonomy, 2022 to 2033
15.3.1. By States
15.3.1.1. Auvergne - Rhône-Alpes
15.3.1.2. Bretagne (Brittany)
15.3.1.3. Bourgogne - Franche-Comté
15.3.1.4. Ile de France (Paris)
15.3.1.5. Rest of France
15.3.2. By Test
15.3.3. By Indication
15.3.4. By End User
15.4. Attractiveness Analysis
15.4.1. By States
15.4.2. By Test
15.4.3. By Indication
15.4.4. By End User
15.5. States Level Analysis and Forecast
15.5.1. Auvergne - Rhône-Alpes Demand Analysis
15.5.1.1. Introduction
15.5.1.2. Demand Analysis and Forecast by Taxonomy
15.5.1.2.1. Test
15.5.1.2.2. By Indication
15.5.1.2.3. By End User
15.5.2. Bretagne (Brittany) Demand Analysis
15.5.2.1. Introduction
15.5.2.2. Demand Analysis and Forecast by Taxonomy
15.5.2.2.1. Test
15.5.2.2.2. By Indication
15.5.2.2.3. By End User
15.5.3. Bourgogne - Franche-Comté Demand Analysis
15.5.3.1. Introduction
15.5.3.2. Demand Analysis and Forecast by Taxonomy
15.5.3.2.1. Test
15.5.3.2.2. By Indication
15.5.3.2.3. By End User
15.5.4. Ile de France (Paris) Demand Analysis
15.5.4.1. Introduction
15.5.4.2. Demand Analysis and Forecast by Taxonomy
15.5.4.2.1. Test
15.5.4.2.2. By Indication
15.5.4.2.3. By End User
16. BENELUX Demand Analysis 2018 to 2022 and Forecast 2022 to 2033
16.1. Introduction
16.2. Historical Size (US$ million) Analysis by Taxonomy, 2018 to 2022
16.3. Current and Future Size (US$ million) Analysis and Forecast by Taxonomy, 2022 to 2033
16.3.1. By Country
16.3.1.1. Belgium
16.3.1.2. Netherlands
16.3.1.3. Luxembourg
16.3.2. By Test
16.3.3. By Indication
16.3.4. By End User
16.4. Attractiveness Analysis
16.4.1. By Country
16.4.2. By Test
16.4.3. By Indication
16.4.4. By End User
16.5. Country Level Analysis and Forecast
16.5.1. Belgium Demand Analysis
16.5.1.1. Introduction
16.5.1.2. Demand Analysis and Forecast by Taxonomy
16.5.1.2.1. Test
16.5.1.2.2. By Indication
16.5.1.2.3. By End User
16.5.2. Netherland Demand Analysis
16.5.2.1. Introduction
16.5.2.2. Demand Analysis and Forecast by Taxonomy
16.5.2.2.1. Test
16.5.2.2.2. By Indication
16.5.2.2.3. By End User
16.5.3. Luxemburg Demand Analysis
16.5.3.1. Introduction
16.5.3.2. Demand Analysis and Forecast by Taxonomy
16.5.3.2.1. Test
16.5.3.2.2. By Indication
16.5.3.2.3. By End User
17. Nordics Demand Analysis 2018 to 2022 and Forecast 2022 to 2033
17.1. Introduction
17.2. Historical Size (US$ million) Analysis by Taxonomy, 2018 to 2022
17.3. Current and Future Size (US$ million) Analysis and Forecast by Taxonomy, 2022 to 2033
17.3.1. By Country
17.3.1.1. Denmark
17.3.1.2. Norway
17.3.1.3. Sweden
17.3.1.4. Finland
17.3.1.5. Rest of Nordics
17.3.2. By Test
17.3.3. By Indication
17.3.4. By End User
17.4. Attractiveness Analysis
17.4.1. By Country
17.4.2. By Test
17.4.3. By Indication
17.4.4. By End User
17.5. Country Level Analysis and Forecast
17.5.1. Denmark Demand Analysis
17.5.1.1. Introduction
17.5.1.2. Demand Analysis and Forecast by Taxonomy
17.5.1.2.1. Test
17.5.1.2.2. By Indication
17.5.1.2.3. By End User
17.5.2. Norway Demand Analysis
17.5.2.1. Introduction
17.5.2.2. Demand Analysis and Forecast by Taxonomy
17.5.2.2.1. Test
17.5.2.2.2. By Indication
17.5.2.2.3. By End User
17.5.3. Sweden Demand Analysis
17.5.3.1. Introduction
17.5.3.2. Demand Analysis and Forecast by Taxonomy
17.5.3.2.1. Test
17.5.3.2.2. By Indication
17.5.3.2.3. By End User
17.5.4. Finland Demand Analysis
17.5.4.1. Introduction
17.5.4.2. Demand Analysis and Forecast by Taxonomy
17.5.4.2.1. Test
17.5.4.2.2. By Indication
17.5.4.2.3. By End User
18. Poland Demand Analysis 2018 to 2022 and Forecast 2022 to 2033
18.1. Introduction
18.2. Historical Size (US$ million) Analysis by Taxonomy, 2018 to 2022
18.3. Current and Future Size (US$ million) Analysis and Forecast by Taxonomy, 2022 to 2033
18.3.1. By Test
18.3.2. By Indication
18.3.3. By End User
18.4. Attractiveness Analysis
18.4.1. By Test
18.4.2. By Indication
18.4.3. By End User
19. Hungary Demand Analysis 2018 to 2022 and Forecast 2022 to 2033
19.1. Introduction
19.2. Historical Size (US$ million) Analysis by Taxonomy, 2018 to 2022
19.3. Current and Future Size (US$ million) Analysis and Forecast by Taxonomy, 2022 to 2033
19.3.1. By Test
19.3.2. By Indication
19.3.3. By End User
19.4. Attractiveness Analysis
19.4.1. By Test
19.4.2. By Indication
19.4.3. By End User
20. Romania Demand Analysis 2018 to 2022 and Forecast 2022 to 2033
20.1. Introduction
20.2. Historical Size (US$ million) Analysis by Taxonomy, 2018 to 2022
20.3. Current and Future Size (US$ million) Analysis and Forecast by Taxonomy, 2022 to 2033
20.3.1. By Test
20.3.2. By Indication
20.3.3. By End User
20.4. Attractiveness Analysis
20.4.1. By Test
20.4.2. By Indication
20.4.3. By End User
21. Czech Republic Demand Analysis 2018 to 2022 and Forecast 2022 to 2033
21.1. Introduction
21.2. Historical Size (US$ million) Analysis by Taxonomy, 2018 to 2022
21.3. Current and Future Size (US$ million) Analysis and Forecast by Taxonomy, 2022 to 2033
21.3.1. By Test
21.3.2. By Indication
21.3.3. By End User
21.4. Attractiveness Analysis
21.4.1. By Test
21.4.2. By Indication
21.4.3. By End User
22. Russia Demand Analysis 2018 to 2022 and Forecast 2022 to 2033
22.1. Introduction
22.2. Historical Size (US$ million) Analysis by Taxonomy, 2018 to 2022
22.3. Current and Future Size (US$ million) Analysis and Forecast by Taxonomy, 2022 to 2033
22.3.1. By Test
22.3.2. By Indication
22.3.3. By End User
22.4. Attractiveness Analysis
22.4.1. By Test
22.4.2. By Indication
22.4.3. By End User
23. Rest of Demand Analysis 2018 to 2022 and Forecast 2022 to 2033
23.1. Introduction
23.2. Historical Size (US$ million) Analysis by Taxonomy, 2018 to 2022
23.3. Current and Future Size (US$ million) Analysis and Forecast by Taxonomy, 2022 to 2033
23.3.1. By Test
23.3.2. By Indication
23.3.3. By End User
23.4. Attractiveness Analysis
23.4.1. By Test
23.4.2. By Indication
23.4.3. By End User
24. Structure Analysis
24.1. Demand Analysis by Tier of Companies
24.2. Share Analysis of Top Players (%)
25. Competition Analysis
25.1. Competition Dashboard
25.2. Competition Benchmarking
25.3. Branding and Promotional Strategies
25.4. Key Development Analysis
25.5. Competition Deep Dive (Tentative List)
25.5.1. Koninklijke Philips N.V
25.5.1.1. Overview
25.5.1.2. Test Portfolio
25.5.1.3. Key Financials
25.5.1.4. SWOT Analysis
25.5.1.5. Key Developments
25.5.1.6. Sales Footprint
25.5.1.7. Strategy Overview
25.5.1.7.1. Strategy
25.5.1.7.2. Test Strategy
25.5.1.7.3. Channel Strategy
25.5.2. F.Hoffmann-La Roche Ltd.
25.5.2.1. Overview
25.5.2.2. Test Portfolio
25.5.2.3. Key Financials
25.5.2.4. SWOT Analysis
25.5.2.5. Key Developments
25.5.2.6. Sales Footprint
25.5.2.7. Strategy Overview
25.5.2.7.1. Strategy
25.5.2.7.2. Test Strategy
25.5.2.7.3. Channel Strategy
25.5.3. Abbott Laboratories, Inc.
25.5.3.1. Overview
25.5.3.2. Test Portfolio
25.5.3.3. Key Financials
25.5.3.4. SWOT Analysis
25.5.3.5. Key Developments
25.5.3.6. Sales Footprint
25.5.3.7. Strategy Overview
25.5.3.7.1. Strategy
25.5.3.7.2. Test Strategy
25.5.3.7.3. Channel Strategy
25.5.4. Bio Rad Laboratories Inc.
25.5.4.1. Overview
25.5.4.2. Test Portfolio
25.5.4.3. Key Financials
25.5.4.4. SWOT Analysis
25.5.4.5. Key Developments
25.5.4.6. Sales Footprint
25.5.4.7. Strategy Overview
25.5.4.7.1. Strategy
25.5.4.7.2. Test Strategy
25.5.4.7.3. Channel Strategy
25.5.5. General Electric (GE HealthCare)
25.5.5.1. Overview
25.5.5.2. Test Portfolio
25.5.5.3. Key Financials
25.5.5.4. SWOT Analysis
25.5.5.5. Key Developments
25.5.5.6. Sales Footprint
25.5.5.7. Strategy Overview
25.5.5.7.1. Strategy
25.5.5.7.2. Test Strategy
25.5.5.7.3. Channel Strategy
25.5.6. QIAGEN N.V.
25.5.6.1. Overview
25.5.6.2. Test Portfolio
25.5.6.3. Key Financials
25.5.6.4. SWOT Analysis
25.5.6.5. Key Developments
25.5.6.6. Sales Footprint
25.5.6.7. Strategy Overview
25.5.6.7.1. Strategy
25.5.6.7.2. Test Strategy
25.5.6.7.3. Channel Strategy
25.5.7. Agilent Technologies, Inc.
25.5.7.1. Overview
25.5.7.2. Test Portfolio
25.5.7.3. Key Financials
25.5.7.4. SWOT Analysis
25.5.7.5. Key Developments
25.5.7.6. Sales Footprint
25.5.7.7. Strategy Overview
25.5.7.7.1. Strategy
25.5.7.7.2. Test Strategy
25.5.7.7.3. Channel Strategy
25.5.8. Becton, Dickinson and Company
25.5.8.1. Overview
25.5.8.2. Test Portfolio
25.5.8.3. Key Financials
25.5.8.4. SWOT Analysis
25.5.8.5. Key Developments
25.5.8.6. Sales Footprint
25.5.8.7. Strategy Overview
25.5.8.7.1. Strategy
25.5.8.7.2. Test Strategy
25.5.8.7.3. Channel Strategy
25.5.9. Cook Group Inc.
25.5.9.1. Overview
25.5.9.2. Test Portfolio
25.5.9.3. Key Financials
25.5.9.4. SWOT Analysis
25.5.9.5. Key Developments
25.5.9.6. Sales Footprint
25.5.9.7. Strategy Overview
25.5.9.7.1. Strategy
25.5.9.7.2. Test Strategy
25.5.9.7.3. Channel Strategy
25.5.10. Danaher (Cepheid)
25.5.10.1. Overview
25.5.10.2. Test Portfolio
25.5.10.3. Key Financials
25.5.10.4. SWOT Analysis
25.5.10.5. Key Developments
25.5.10.6. Sales Footprint
25.5.10.7. Strategy Overview
25.5.10.7.1. Strategy
25.5.10.7.2. Test Strategy
25.5.10.7.3. Channel Strategy
25.5.11. Siemens Healthcare GmbH
25.5.11.1. Overview
25.5.11.2. Test Portfolio
25.5.11.3. Key Financials
25.5.11.4. SWOT Analysis
25.5.11.5. Key Developments
25.5.11.6. Sales Footprint
25.5.11.7. Strategy Overview
25.5.11.7.1. Strategy
25.5.11.7.2. Test Strategy
25.5.11.7.3. Channel Strategy
25.5.12. Thermo Fisher Scientific Inc.
25.5.12.1. Overview
25.5.12.2. Test Portfolio
25.5.12.3. Key Financials
25.5.12.4. SWOT Analysis
25.5.12.5. Key Developments
25.5.12.6. Sales Footprint
25.5.12.7. Strategy Overview
25.5.12.7.1. Strategy
25.5.12.7.2. Test Strategy
25.5.12.7.3. Channel Strategy
25.5.13. Illumina, Inc.
25.5.13.1. Overview
25.5.13.2. Test Portfolio
25.5.13.3. Key Financials
25.5.13.4. SWOT Analysis
25.5.13.5. Key Developments
25.5.13.6. Sales Footprint
25.5.13.7. Strategy Overview
25.5.13.7.1. Strategy
25.5.13.7.2. Test Strategy
25.5.13.7.3. Channel Strategy
25.5.14. Hologic, Inc
25.5.14.1. Overview
25.5.14.2. Test Portfolio
25.5.14.3. Key Financials
25.5.14.4. SWOT Analysis
25.5.14.5. Key Developments
25.5.14.6. Sales Footprint
25.5.14.7. Strategy Overview
25.5.14.7.1. Strategy
25.5.14.7.2. Test Strategy
25.5.14.7.3. Channel Strategy
25.5.15. Argon Medical Devices
25.5.15.1. Overview
25.5.15.2. Test Portfolio
25.5.15.3. Key Financials
25.5.15.4. SWOT Analysis
25.5.15.5. Key Developments
25.5.15.6. Sales Footprint
25.5.15.7. Strategy Overview
25.5.15.7.1. Strategy
25.5.15.7.2. Test Strategy
25.5.15.7.3. Channel Strategy
25.5.16. Vortex Biosciences, Inc.
25.5.16.1. Overview
25.5.16.2. Test Portfolio
25.5.16.3. Key Financials
25.5.16.4. SWOT Analysis
25.5.16.5. Key Developments
25.5.16.6. Sales Footprint
25.5.16.7. Strategy Overview
25.5.16.7.1. Strategy
25.5.16.7.2. Test Strategy
25.5.16.7.3. Channel Strategy
25.5.17. Canon Medical Systems Corporation
25.5.17.1. Overview
25.5.17.2. Test Portfolio
25.5.17.3. Key Financials
25.5.17.4. SWOT Analysis
25.5.17.5. Key Developments
25.5.17.6. Sales Footprint
25.5.17.7. Strategy Overview
25.5.17.7.1. Strategy
25.5.17.7.2. Test Strategy
25.5.17.7.3. Channel Strategy
25.5.18. Merit Medical Systems
25.5.18.1. Overview
25.5.18.2. Test Portfolio
25.5.18.3. Key Financials
25.5.18.4. SWOT Analysis
25.5.18.5. Key Developments
25.5.18.6. Sales Footprint
25.5.18.7. Strategy Overview
25.5.18.7.1. Strategy
25.5.18.7.2. Test Strategy
25.5.18.7.3. Channel Strategy
26. Assumptions and Acronyms Used27. Research Methodology
List of Tables
Table 01: Sales (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Test
Table 02: Sales (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Test
Table 03: Sales (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication
Table 04: Sales (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
Table 05: Sales(US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
Table 06: Sales (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
Table 07: United Kingdom Sales(US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By States
Table 08: United Kingdom Sales (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Test
Table 09: United Kingdom Sales (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Test
Table 10: United Kingdom Sales (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication
Table 11: United Kingdom Sales (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
Table 12: Germany Sales (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By States
Table 13: Germany Sales (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Test
Table 14: Germany Sales (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Test
Table 15: Germany Sales (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication
Table 16: Germany Sales (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
Table 17: Spain Sales (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By States
Table 18: Spain Sales (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Test
Table 19: Spain Sales (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Test
Table 20: Spain Sales (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication
Table 21: Spain Sales (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
Table 22: Italy Sales (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By States
Table 23: Italy Sales (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Test
Table 24: Italy Sales (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Test
Table 25: Italy Sales (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication
Table 26: Italy Sales (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
Table 27: France Sales (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By States
Table 28: France Sales (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Test
Table 29: France Sales (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Test
Table 30: France Sales (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication
Table 31: France Sales (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
Table 32: BENELUX Sales (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By States
Table 33: BENELUX Sales (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Test
Table 34: BENELUX Sales (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Test
Table 35: BENELUX Sales (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication
Table 36: BENELUX Sales (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
Table 37: Nordics Sales (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By States
Table 38: Nordics Sales (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Test
Table 39: Nordics Sales (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Test
Table 40: Nordics Sales (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication
Table 41: Nordics Sales (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
Table 42: Poland Sales (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Test
Table 43: Poland Sales (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Test
Table 44: Poland Sales (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication
Table 45: Poland Sales (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
Table 46: Hungary Sales (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Test
Table 47: Hungary Sales (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Test
Table 48: Hungary Sales (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication
Table 49: Hungary Sales (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
Table 50: Romania Sales (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Test
Table 51: Romania Sales (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Test
Table 52: Romania Sales (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication
Table 53: Romania Sales (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
Table 54: Russia Sales (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Test
Table 55: Russia Sales (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Test
Table 56: Russia Sales (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication
Table 57: Russia Sales (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
Table 58: Czech Republic Sales (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Test
Table 59: Czech Republic Sales (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Test
Table 60: Czech Republic Sales (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication
Table 61: Czech Republic Sales (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
Table 62: Rest of Sales (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Test
Table 63: Rest of Sales (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Test
Table 64: Rest of Sales (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication
Table 65: Rest of Sales (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
List of Charts
Figure 01: Value Share By Test (2022 A)
Figure 02: Value Share By Indication (2022 A)
Figure 03: Value Share By End User (2022 A)
Figure 04: Value Share By Region (2022 A)
Figure 05: Value Analysis (US$ million), 2018 to 2022
Figure 06: Value Forecast (US$ million), 2023 to 2033
Figure 07: Absolute $ Opportunity, 2023 to 2033
Figure 08: Share Analysis (%) By Test, 2023 and 2033
Figure 09: Y-o-Y Growth (%) By Test, 2023 to 2033
Figure 10: Attractiveness Analysis By Test, 2023 to 2033
Figure 11: Share Analysis (%) By Indication, 2023 and 2033
Figure 12: Y-o-Y Growth (%) By Indication, 2023 to 2033
Figure 13: Attractiveness Analysis By Indication, 2023 to 2033
Figure 14: Share Analysis (%) By End User, 2023 and 2033
Figure 15: Y-o-Y Growth (%) By End User, 2023 to 2033
Figure 16: Attractiveness Analysis By End User, 2023 to 2033
Figure 17: Share Analysis (%) By Region, 2023 and 2033
Figure 18: Y-o-Y Growth (%) By Region, 2023 to 2033
Figure 19: Attractiveness Analysis By Region, 2023 to 2033
Figure 20: United Kingdom Value Share By Test (2022 A)
Figure 21: United Kingdom Value Share By Indication (2022 A)
Figure 22: United Kingdom Value Share By End User (2022 A)
Figure 23: United Kingdom Value Share By States (2022 A)
Figure 24: United Kingdom Value Analysis (US$ million), 2018 to 2022
Figure 25: United Kingdom Value Forecast (US$ million), 2023 to 2033
Figure 26: United Kingdom Attractiveness Analysis, By Test
Figure 27: United Kingdom Attractiveness Analysis, By Indication
Figure 28: United Kingdom Attractiveness Analysis, By End User
Figure 29: United Kingdom Attractiveness Analysis, By States
Figure 30: England Share Analysis (%), By Test, 2022 and 2033
Figure 31: England Share Analysis (%), by Indication, 2022 and 2033
Figure 32: England Share Analysis (%), by End User, 2022 and 2033
Figure 33: Wales Share Analysis (%), By Test, 2022 and 2033
Figure 34: Wales Share Analysis (%), by Indication, 2022 and 2033
Figure 35: Wales Share Analysis (%), by End User, 2022 and 2033
Figure 36: Northern Ireland Share Analysis (%), By Test, 2022 and 2033
Figure 37: Northern Ireland Share Analysis (%), by Indication, 2022 and 2033
Figure 38: Northern Ireland Share Analysis (%), by End User, 2022 and 2033
Figure 39: Scotland Share Analysis (%), By Test, 2022 and 2033
Figure 40: Scotland Share Analysis (%), by Indication, 2022 and 2033
Figure 41: Scotland Share Analysis (%), by End User, 2022 and 2033
Figure 42: Germany Value Share By Test (2022 A)
Figure 43: Germany Value Share By Indication (2022 A)
Figure 44: Germany Value Share By End User (2022 A)
Figure 45: Germany Value Share By States (2022 A)
Figure 46: Germany Value Analysis (US$ million), 2018 to 2022
Figure 47: Germany Value Forecast (US$ million), 2023 to 2033
Figure 48: Germany Attractiveness Analysis, By Test
Figure 49: Germany Attractiveness Analysis, By Indication
Figure 50: Germany Attractiveness Analysis, By End User
Figure 51: Germany Attractiveness Analysis, By States
Figure 52: Baden-Württemberg Share Analysis (%), By Test, 2022 and 2033
Figure 53: Baden-Württemberg Share Analysis (%), by Indication, 2022 and 203353
Figure 54: Baden-Württemberg Share Analysis (%), by End User, 2022 and 2033
Figure 55: Bavaria Share Analysis (%), By Test, 2022 and 2033
Figure 56: Bavaria Share Analysis (%), by Indication, 2022 and 2033
Figure 57: Bavaria Share Analysis (%), by End User, 2022 and 2033
Figure 58: Lower Saxony Share Analysis (%), By Test, 2022 and 2033
Figure 59: Lower Saxony Share Analysis (%), by Indication, 2022 and 2033
Figure 60: Lower Saxony Share Analysis (%), by End User, 2022 and 2033
Figure 61: Hesse Share Analysis (%), By Test, 2022 and 2033
Figure 62: Hesse Share Analysis (%), by Indication, 2022 and 2033
Figure 63: Hesse Share Analysis (%), by End User, 2022 and 2033
Figure 64: Spain Value Share By Test (2022 A)
Figure 65: Spain Value Share By Indication (2022 A)
Figure 66: Spain Value Share By End User (2022 A)
Figure 67: Spain Value Share By States (2022 A)
Figure 68: Spain Value Analysis (US$ million), 2018 to 2022
Figure 69: Spain Value Forecast (US$ million), 2023 to 2033
Figure 70: Spain Attractiveness Analysis, By Test
Figure 71: Spain Attractiveness Analysis, By Indication
Figure 72: Spain Attractiveness Analysis, By End User
Figure 73: Spain Attractiveness Analysis, By States
Figure 74: Madrid Share Analysis (%), By Test, 2022 and 2033
Figure 75: Madrid Share Analysis (%), by Indication, 2022 and 2033
Figure 76: Madrid Share Analysis (%), by End User, 2022 and 2033
Figure 77: Barcelona Share Analysis (%), By Test, 2022 and 2033
Figure 78: Barcelona Share Analysis (%), by Indication, 2022 and 2033
Figure 79: Barcelona Share Analysis (%), by End User, 2022 and 2033
Figure 80: Valencia Share Analysis (%), By Test, 2022 and 2033
Figure 81: Valencia Share Analysis (%), by Indication, 2022 and 2033
Figure 82: Valencia Share Analysis (%), by End User, 2022 and 2033
Figure 83: Seville Share Analysis (%), By Test, 2022 and 2033
Figure 84: Seville Share Analysis (%), by Indication, 2022 and 2033
Figure 85: Seville Share Analysis (%), by End User, 2022 and 2033
Figure 86: Italy Value Share By Test (2022 A)
Figure 87: Italy Value Share By Indication (2022 A)
Figure 88: Italy Value Share By End User (2022 A)
Figure 89: Italy Value Share By States (2022 A)
Figure 90: Italy Value Analysis (US$ million), 2018 to 2022
Figure 91: Italy Value Forecast (US$ million), 2023 to 2033
Figure 92: Italy Attractiveness Analysis, By Test
Figure 93: Italy Attractiveness Analysis, By Indication
Figure 94: Italy Attractiveness Analysis, By End User
Figure 95: Italy Attractiveness Analysis, By States
Figure 96: Rome Share Analysis (%), By Test, 2022 and 2033
Figure 97: Rome Share Analysis (%), by Indication, 2022 and 2033
Figure 98: Rome Share Analysis (%), by End User, 2022 and 2033
Figure 99: Abruzzo Share Analysis (%), By Test, 2022 and 2033
Figure 100: Abruzzo Share Analysis (%), by Indication, 2022 and 2033
Figure 101: Abruzzo Share Analysis (%), by End User, 2022 and 2033
Figure 102: Basilicata Share Analysis (%), By Test, 2022 and 2033
Figure 103: Basilicata Share Analysis (%), by Indication, 2022 and 2033
Figure 104: Basilicata Share Analysis (%), by End User, 2022 and 2033
Figure 105: Calabria Share Analysis (%), By Test, 2022 and 2033
Figure 106: Calabria Share Analysis (%), by Indication, 2022 and 2033
Figure 107: Calabria Share Analysis (%), by End User, 2022 and 2033
Figure 108: France Value Share By Test (2022 A)
Figure 109: France Value Share By Indication (2022 A)
Figure 110: France Value Share By End User (2022 A)
Figure 111: France Value Share By States (2022 A)
Figure 112: France Value Analysis (US$ million), 2018 to 2022
Figure 113: France Value Forecast (US$ million), 2023 to 2033
Figure 114: France Attractiveness Analysis, By Test
Figure 115: France Attractiveness Analysis, By Indication
Figure 116: France Attractiveness Analysis, By End User
Figure 117: France Attractiveness Analysis, By States
Figure 118: Auvergne - Rhône-Alpes Share Analysis (%), By Test, 2022 and 2033
Figure 119: Auvergne - Rhône-Alpes Share Analysis (%), by Indication, 2022 and 2033
Figure 120: Auvergne - Rhône-Alpes Share Analysis (%), by End User, 2022 and 2033
Figure 121: Bretagne (Brittany) Share Analysis (%), By Test, 2022 and 2033
Figure 122: Bretagne (Brittany) Share Analysis (%), by Indication, 2022 and 2033
Figure 123: Bretagne (Brittany) Share Analysis (%), by End User, 2022 and 2033
Figure 124: Bourgogne - Franche-Comté Share Analysis (%), By Test, 2022 and 2033
Figure 125: Bourgogne - Franche-Comté Share Analysis (%), by Indication, 2022 and 2033
Figure 126: Bourgogne - Franche-Comté Share Analysis (%), by End User, 2022 and 2033
Figure 127: Ile de France (Paris) Share Analysis (%), By Test, 2022 and 2033
Figure 128: Ile de France (Paris) Share Analysis (%), by Indication, 2022 and 2033
Figure 129: Ile de France (Paris) Share Analysis (%), by End User, 2022 and 2033
Figure 130: BENELUX Value Share By Test (2022 A)
Figure 131: BENELUX Value Share By Indication (2022 A)
Figure 132: BENELUX Value Share By End User (2022 A)
Figure 133: BENELUX Value Share By States (2022 A)
Figure 134: BENELUX Value Analysis (US$ million), 2018 to 2022
Figure 135: BENELUX Value Forecast (US$ million), 2023 to 2033
Figure 136: BENELUX Attractiveness Analysis, By Test
Figure 137: BENELUX Attractiveness Analysis, By Indication
Figure 138: BENELUX Attractiveness Analysis, By End User
Figure 139: BENELUX Attractiveness Analysis, By States
Figure 140: Belgium Share Analysis (%), By Test, 2022 and 2033
Figure 141: Belgium Share Analysis (%), by Indication, 2022 and 2033
Figure 142: Belgium Share Analysis (%), by End User, 2022 and 2033
Figure 143: Netherlands Share Analysis (%), By Test, 2022 and 2033
Figure 144: Netherlands Share Analysis (%), by Indication, 2022 and 2033
Figure 145: Netherlands Share Analysis (%), by End User, 2022 and 2033
Figure 146: Luxembourg Share Analysis (%), By Test, 2022 and 2033
Figure 147: Luxembourg Share Analysis (%), by Indication, 2022 and 2033
Figure 148: Luxembourg Share Analysis (%), by End User, 2022 and 2033
Figure 149: Nordics Value Share By Test (2022 A)
Figure 150: Nordics Value Share By Indication (2022 A)
Figure 151: Nordics Value Share By End User (2022 A)
Figure 152: Nordics Value Share By States (2022 A)
Figure 153: Nordics Value Analysis (US$ million), 2018 to 2022
Figure 154: Nordics Value Forecast (US$ million), 2023 to 2033
Figure 155: Nordics Attractiveness Analysis, By Test
Figure 156: Nordics Attractiveness Analysis, By Indication
Figure 157: Nordics Attractiveness Analysis, By End User
Figure 158: Nordics Attractiveness Analysis, By States
Figure 159: Denmark Share Analysis (%), By Test, 2022 and 2033
Figure 160: Denmark Share Analysis (%), by Indication, 2022 and 2033
Figure 161: Denmark Share Analysis (%), by End User, 2022 and 2033
Figure 162: Norway Share Analysis (%), By Test, 2022 and 2033
Figure 163: Norway Share Analysis (%), by Indication, 2022 and 2033
Figure 164: Norway Share Analysis (%), by End User, 2022 and 2033
Figure 165: Sweden Share Analysis (%), By Test, 2022 and 2033
Figure 166: Sweden Share Analysis (%), by Indication, 2022 and 2033
Figure 167: Sweden Share Analysis (%), by End User, 2022 and 2033
Figure 168: Finland Share Analysis (%), By Test, 2022 and 2033
Figure 169: Finland Share Analysis (%), by Indication, 2022 and 2033
Figure 170: Finland Share Analysis (%), by End User, 2022 and 2033
Figure 171: Poland Value Share By Test (2022 A)
Figure 172: Poland Value Share By Indication (2022 A)
Figure 173: Poland Value Share By Indication (2022 A)
Figure 174: Poland Value Analysis (US$ million), 2018 to 2022
Figure 175: Poland Value Forecast (US$ million), 2023 to 2033
Figure 176: Poland Attractiveness Analysis, By Test
Figure 177: Poland Attractiveness Analysis, By Indication
Figure 178: Poland Attractiveness Analysis, By End User
Figure 179: Hungary Value Share By Test (2022 A)
Figure 180: Hungary Value Share By Indication (2022 A)
Figure 181: Hungary Value Share By Indication (2022 A)
Figure 182: Hungary Value Analysis (US$ million), 2018 to 2022
Figure 183: Hungary Value Forecast (US$ million), 2023 to 2033
Figure 184: Hungary Attractiveness Analysis, By Test
Figure 185: Hungary Attractiveness Analysis, By Indication
Figure 186: Hungary Attractiveness Analysis, By End User
Figure 187: Romania Value Share By Test (2022 A)
Figure 188: Romania Value Share By Indication (2022 A)
Figure 189: Romania Value Share By Indication (2022 A)
Figure 190: Romania Value Analysis (US$ million), 2018 to 2022
Figure 191: Romania Value Forecast (US$ million), 2023 to 2033
Figure 192: Romania Attractiveness Analysis, By Test
Figure 193: Romania Attractiveness Analysis, By Indication
Figure 194: Romania Attractiveness Analysis, By End User
Figure 195: Russia Value Share By Test (2022 A)
Figure 196: Russia Value Share By Indication (2022 A)
Figure 197: Russia Value Share By Indication (2022 A)
Figure 198: Russia Value Analysis (US$ million), 2018 to 2022
Figure 199: Russia Value Forecast (US$ million), 2023 to 2033
Figure 200: Russia Attractiveness Analysis, By Test
Figure 201: Russia Attractiveness Analysis, By Indication
Figure 202: Russia Attractiveness Analysis, By End User
Figure 203: Czech Republic Value Share By Test (2022 A)
Figure 204: Czech Republic Value Share By Indication (2022 A)
Figure 205: Czech Republic Value Share By Indication (2022 A)
Figure 206: Czech Republic Value Analysis (US$ million), 2018 to 2022
Figure 207: Czech Republic Value Forecast (US$ million), 2023 to 2033
Figure 208: Czech Republic Attractiveness Analysis, By Test
Figure 209: Czech Republic Attractiveness Analysis, By Indication
Figure 210: Czech Republic Attractiveness Analysis, By End User
Figure 211: Rest of Value Share By Test (2022 A)
Figure 212: Rest of Value Share By Indication (2022 A)
Figure 213: Rest of Value Share By Indication (2022 A)
Figure 214: Rest of Value Analysis (US$ million), 2018 to 2022
Figure 215: Rest of Value Forecast (US$ million), 2023 to 2033
Figure 216: Rest of Attractiveness Analysis, By Test
Figure 217: Rest of Attractiveness Analysis, By Indication
Figure 218: Rest of Attractiveness Analysis, By End User
